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MaBACKGROUND Previous meta-analyses have investigated the relative safety and efﬁcacy proﬁles of different types of
drug-eluting stents (DES) and bare-metal stents (BMS); however, most prior trials in these meta-analyses reported
follow-up to only 1 year, and as such, the relative long-term safety and efﬁcacy of these devices are unknown. Many
recent studies have now reported extended follow-up data.
OBJECTIVES This study sought to investigate the long-term safety and efﬁcacy of durable polymer-based DES,
bioabsorbable polymer-based biolimus-eluting stents (BES), and BMS by means of network meta-analysis.
METHODS Randomized controlled trials comparing DES to each other or to BMS were searched through MEDLINE,
EMBASE, and Cochrane databases and proceedings of international meetings. Information on study design, inclusion and
exclusion criteria, sample characteristics, and clinical outcomes was extracted.
RESULTS Fifty-one trials that included a total of 52,158 randomized patients with follow-up duration $3 years were
analyzed. At a median follow-up of 3.8 years, cobalt-chromium everolimus-eluting stents (EES) were associated with
lower rates of mortality, deﬁnite stent thrombosis (ST), and myocardial infarction than BMS, paclitaxel-eluting stents
(PES), and sirolimus-eluting stents (SES) and less ST than BES. Phosphorylcholine-based zotarolimus-eluting stents had
lower rates of deﬁnite ST than SES and lower rates of myocardial infarction than BMS and PES. The late rates of target-
vessel revascularization were reduced with all DES compared with BMS, with cobalt-chromium EES, platinum chromium-
EES, SES, and BES also having lower target-vessel revascularization rates than PES.
CONCLUSIONS After amedian follow-upof3.8years, allDESdemonstrated superior efﬁcacy comparedwithBMS.Among
DES, second-generation devices have substantially improved long-term safety and efﬁcacy outcomes compared with
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ABB R E V I A T I O N S AND
ACRONYM S
BES = biolimus-eluting stent(s)
BMS = bare-metal stent(s)
CI = credible interval
CoCr-EES = cobalt-chromium
everolimus-eluting stent(s)
DES = drug-eluting stent(s)
HR = hazard ratio
MI = myocardial infarction
PC-ZES = phosphorylcholine-
based zotarolimus-eluting stent(s)
PES = paclitaxel-eluting stent(s)
PtCr-EES = platinum chromium
everolimus-eluting stent(s)
RCT = randomized controlled trial
Re-ZES = Resolute zotarolimus-
eluting stent(s)
SES = sirolimus-eluting stent(s)
ST = stent thrombosis
TVR = target-vessel
revascularization
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2497A lthough ﬁrst-generation sirolimus-elutingstents (SES) (Cypher, Cordis Corp., MiamiLakes, Florida) and paclitaxel-eluting stents
(PES) (Taxus, Boston Scientiﬁc, Natick, Massachu-
setts) signiﬁcantly reduced the risk of restenosis and
ischemia-driven target-vessel revascularization (TVR)
compared with bare-metal stents (BMS) (1,2), an
ongoing propensity for very late stent thrombosis
(ST) and adverse events emerged with both types of
stent (3). To mitigate these risks, newer devices were
developed that used novel stent materials, platforms,
and delivery systems, with more biocompatible poly-
mers (both durable and bioresorbable) than their pre-
decessors. Several randomized controlled trials
(RCTs) and meta-analyses have suggested that these
newer devices may have a better safety proﬁle not
only compared with ﬁrst-generation drug-eluting
stents (DES) but also when compared with BMS (4,5);
however, most of these studies had a limited follow-
up of 1 year, with very few reporting data beyond 2
years. The long-term relative safety and efﬁcacy of
second-generation DES have therefore not been inves-
tigated in depth.FIGURE 1 Evidence Network Between Stents Included in
Meta-Analysis
BES
BMS
CoCr-EES
PES
PtCr-EES
SES
PC-ZES
Re-ZES
BES ¼ biolimus-eluting stent(s); BMS ¼ bare-metal stent(s);
CoCr-EES ¼ cobalt-chromium everolimus-eluting stent(s); PC-
ZES ¼ phosphorylcholine polymer–based zotarolimus-eluting
stent(s); PES ¼ paclitaxel-eluting stent(s); PtCr-EES ¼ platinum-
chromium everolimus-eluting stent(s); Re-ZES ¼ Resolute
zotarolimus-eluting stent(s); SES ¼ sirolimus-eluting stent(s).
SEE PAGE 2508An example of the importance of extended follow-
up may be seen from the PROTECT trial (Patient-
Related Outcomes With Endeavor Versus Cypher
Stenting Trial), in which reduced rates of ST with
phosphorylcholine-based zotarolimus-eluting stents
(PC-ZES) (Medtronic, Santa Rosa, California) com-
pared with SES emerged only at 4 years of follow-up
(6). Similarly, any advantages of bioabsorbable
polymer-based DES compared with permanent
polymer-based DES might only be expected to be
present at long-term follow-up.
Since the publication of the most recent meta-
analysis comparing different types of DES with each
other or with BMS (7), several RCTs have signiﬁcantly
extended their period of surveillance, reporting data
at 3 to 6 years after stent implantation (8–20). For this
reason, to examine the long-term relative safety and
efﬁcacy of different DES and BMS, we performed an
updated network meta-analysis including only trials
with a follow-up duration of at least 3 years.
METHODS
OBJECTIVES, DEFINITIONS, AND STUDY DESIGN. The
primary endpoint of this network meta-analysis was
the long-term rate of deﬁnite ST deﬁned according
to the Academic Research Consortium criteria (21).
Only RCTs investigating currently U.S. Food and Drug
Administration (FDA)–approved DES and BMS witha follow-up duration of $3 years were
included in the meta-analysis. In addition,
we also included studies with biolimus-
eluting stents (BES) (BioMatrix, Bio-
sensors, Newport Beach, California; and
Nobori, Terumo Clinical Supply, Kakami-
gahara, Japan), because these devices have
been investigated extensively in several
large-scale RCTs (22–26) and are the most
widely used bioabsorbable polymer-based
DES outside the United States. Thus, the
DES studied in the present report were SES,
PES, cobalt-chromium everolimus-eluting
stents (CoCr-EES) (Abbott Vascular, Santa
Clara, California), platinum-chromium EES
(PtCr-EES) (Boston Scientiﬁc), PC-ZES, Re-
solute ZES (Re-ZES) (Medtronic), and BES.
Secondary pre-speciﬁed endpoints in-
cluded long-term rates of Academic
Research Consortium deﬁnite/probable ST
and very late (>1 year) deﬁnite and deﬁ-
nite/probable ST, as well as death, cardiac
death, myocardial infarction (MI), and TVR.
This review was performed according to PRISMA
(Preferred Reporting Items for Systematic Reviews and
Meta-analyses) statements.
DATA SOURCE AND STUDY SELECTION. Relevant
RCTs to include in this meta-analysis were searched
through MEDLINE, the Cochrane database, the
EMBASE database, the Transcatheter Cardiovascular
TABLE 1 Randomized Controlled Trials Included in Network Meta-Analysis
Study/First Author* Primary Endpoint Design
Randomization
Ratio
Latest
Follow-Up
Available Stent Comparators
Results of the
Primary Endpoint
COMPARE Death, MI, TVR at 1 yr Single center, superiority 1:1 5 yrs CoCr-EES/PES
1,800 (897/903)
CoCr-EES superior to PES
COMPARE II Cardiac death, nonfatal MI,
TVR at 1 yr
Multicenter, noninferiority 1:2 3 yrs CoCr-EES/BP-BES
2,707 (912/1,795)
BES noninferior to
CoCr-EES
DES DIABETES In-segment restenosis at
6 months
Multicenter, superiority 1:1 4 yrs SES/PES
400(200/200)
SES superior to PES
ENDEAVOR II TVF at 9 months Multicenter, superiority of
PC-ZES vs. BMS
1:1 5 yrs PC-ZES/BMS
1,193 (597/596)
PC-ZES superior to BMS
ENDEAVOR III Late lumen loss at
8 months
Multicenter, noninferiority 1:3 5 yrs SES/PC-ZES
436 (113/323)
PC-ZES inferior to SES
ENDEAVOR IV TVF at 9 months Multicenter, noninferiority 1:1 3 yrs PES/PC-ZES
1,548 (775/773)
PES noninferior to
PC-ZES
HORIZONS-AMI 1) TLR at 1 yr; 2) death, MI,
stroke, or ST at 1 yr
Multicenter, superiority for
TLR; noninferiority for
death, MI, stroke, ST
3:1 3 yrs BMS/PES
3,006 (2,257/749)
PES superior for TLR and
noninferior for clinical
endpoints
ISAR DESIRE Late lumen loss at 8 months Two-center, noninferiority 1:1 5 yrs PES/SES
450 (225/225)
PES noninferior to SES
ISAR DIABETES Late lumen loss at 6 months Two-center, noninferiority 1:1 5 yrs PES/SES
250 (125/125)
PES inferior to SES
ISAR SMART III In-stent late luminal loss at 8
months
Two-center, noninferiority 1:1 5 yrs PES/SES
360 (180/180)
PES inferior to SES
ISAR TEST IV Cardiac death, MI, and TLR
at 1 yr
Two-center, noninferiority 1:1 3 yrs CoCr-EES/SES
1,304 (652/652)
CoCr-EES noninferior to
SES
Kim et al. Cardiac death, MI, TLR Multicenter, superiority 1:1 3 yrs PES/SES
169 (84/85)
PES nonsuperior to SES
LEADERS Cardiac death, MI, TVR at
9 months
Multicenter, noninferiority 1:1 4 yrs BP-BES/SES
1,707 (857/850)
BES noninferior to
BP-SES
MISSION ! In-segment late luminal loss
at 9 months
Single center, noninferiority 1:1 5 yrs BMS/SES
310 (152/158)
SES superior to BMS
MULTISTRATEGY Death, MI, clinically driven
TVR at 8 months
Multicenter, superiority 1:1 3 yrs BMS/SES
744 (372/372)
SES superior to BMS
NAPLES Death, nonfatal MI, clinically
driven TVR at 3 yrs
Single center, superiority 1:1:1 3 yrs PES/SES/PC-ZES
226 (75/76/75)
PES and SES superior to
PC-ZES
NOBORI I phase I In-stent late loss at
9 months
Multicenter, noninferiority 1:2 5 yrs BP-BES/PES
120 (35/85)
BP-BES noninferior to
PES
NOBORI JAPAN TVF at 9 months Multicenter, noninferiority 3:2 3 yrs BP-BES/SES
326 (194/132)
BP-BES noninferior to
SES
Pasceri et al. Death, MI, recurrent
ischemia at 1 yr
Single center, safety outcome 1:1 6 yrs BMS/SES
65 (33/32)
No signiﬁcant differences
between stents
PASEO TLR at 12 months Single center, superiority 1:1:1 4 yrs BMS/PES/SES
270 (90/90/90)
PES and SES superior to
BMS
PASSION Cardiac death, MI, TLR
at 2 yrs
Two center, superiority 1:1 5 yrs BMS/PES
619 (310/309)
Superiority not
demonstrated
PLATINUM TLF at 1 yr Multicenter, noninferiority 1:1 3 yrs PtCr-EES/CoCr-EES
1,530 (768/762)
PtCr-EES noninferior to
CoCr-EES
PRISON II Angiographic in-segment
restenosis at 6 months
Two center, superiority 1:1 3 yrs BMS/SES
200 (100/100)
SES superior to BMS
PROSIT Death, MI, TVR, ST at 1 yr Multicenter, superiority 1:1 3 yrs PES/SES
308 (154/154)
Superiority not
demonstrated
PROTECT Deﬁnite or probable ST
at 3 yrs
Multicenter, superiority 1:1 4 yrs C-SES vs. E-ZES
8,791 (4,352/4,357)
E-ZES nonsuperior to
C-SES
RACES MI Cardiac death, reinfarction,
deﬁnite or probable ST,
and TVR at 3 yrs
Single center, superiority 1:1 3 yrs EES/SES
500 (250/250)
EES has similar efﬁcacy as
SES but is associated
with a signiﬁcant
reduction in ST
RAVEL In-stent late lumen loss at
6 months
Multicenter, superiority 1:1 4 yrs BMS/SES
238 (120/118)
SES superior to BMS
RESOLUTE TLF at 12 months Multicenter, noninferiority 1:1 4 yrs CoCr-EES/Re-ZES
2,292 (1,152/1,140)
Re-ZES noninferior to
CoCr-EES
SCANDSTENT Minimal lumen diameter at
6 months
Multicenter, superiority 1:1 3 yrs SES/BMS
322 (163/159)
SES superior to BMS
SCORPIUS Late luminal loss at
12 months
Multicenter, superiority 1:1 5 yrs SES/BMS
200 (98/102)
SES superior to BMS
Continued on the next page
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TABLE 1 Continued
Study/First Author* Primary Endpoint Design
Randomization
Ratio
Latest
Follow-Up
Available Stent Comparators
Results of the
Primary Endpoint
SESAMI Binary restenosis at 1 yr Single center, superiority 1:1 5 yrs BMS/SES
320 (160/160)
SES superior to BMS
SIRIUS TVF at 9 months Multicenter, superiority 1:1 4 yrs BMS/SES
1,058 (533/525)
SES superior to BMS
E-SIRIUS In-stent minimum lumen
diameter at 8 months
Multicenter, superiority 1:1 4 yrs BMS/SES
352 (175/177)
SES superior to BMS
C-SIRIUS In-stent minimum lumen
diameter at 8 months
Multicenter, superiority 1:1 4 yrs BMS/SES
100 (50/50)
SES superior to BMS
SIRTAX LATE Cardiac death, MI, TLR at
9 months
Single center, superiority 1:1 5 yrs PES/SES
1,012 (509/503)
Superiority not
demonstrated
SORT OUT III Cardiac death, MI, TVR at
9 months
Multicenter, superiority 1:1 5 yrs SES/PC-ZES
2,332 (1,170/1,162)
SES superior to PC-ZES
SORT OUT IV Cardiac death, MI, deﬁnite ST,
and TVR at 9 months
Multicenter, noninferiority 1:1 5 yrs CoCr-EES/SES
2,774 (1,390/1,384)
CoCr-EES noninferior
to SES
SORT OUT V Cardiac death, MI, deﬁnite ST
and clinically driven TVR
at 9 months
Multicenter, noninferiority 1:1 3 yrs BP-BES/SES
2,468 (1,229/1,239)
Noninferiority not
demonstrated
SOS Angiographic restenosis at
12 months
Multicenter, superiority 1:1 3 yrs BMS/PES
80 (41/39)
PES superior to BMS
SPIRIT I In-stent late loss at 180 days Multicenter, superiority 1:1 5 yrs CoCr-EES/BMS
60 (28/32)
CoCr-EES superior to BMS
SPIRIT II In-stent late loss at 6 months Multicenter, noninferiority 3:1 5 yrs CoCr-EES/PES
300 (223/77)
CoCr-EES noninferior
to PES
SPIRIT III In-segment late loss at
9 months
Multicenter, noninferiority
or superiority
2:1 5 yrs CoCr-EES/PES
1,002 (669/333)
CoCr-EES superior to PES
SPIRIT IV TLF at 1 yr Multicenter, noninferiority
or superiority
2:1 3 yrs CoCr-EES/PES
3,687 (2,458/1,229)
CoCr-EES superior to PES
STRATEGY Death, MI, stroke, binary
restenosis at 8 months
Two center, superiority 1:1 5 yrs BMS/SES
175 (87/88)
SES superior to BMS
TAXI Cardiac death, MI, TLR at
6 months
Single center, superiority 1:1 3 yrs PES/SES
202 (100/102)
Superiority not
demonstrated
TAXUS I Death, MI, TVR, ST at
12 months
Multicenter, safety study 1:1 4 yrs BMS/PES
61 (31/30)
PES as safe as BMS
TAXUS II Neointimal proliferation by
IVUS at 6 months
Multicenter, superiority 1:1 4 yrs BMS/PES
536 (266/270)
PES superior to BMS
TAXUS IV Ischemia-driven TVR at
9 months
Multicenter, superiority 1:1 4 yrs BMS/PES
1,314 (662/652)
PES superior to BMS
TAXUS V Ischemia-driven TVR at
9 months
Multicenter, superiority 1:1 4 yrs BMS/PES
1,156 (577/579)
PES superior to BMS
TAXUS VI TVR 9 months Multicenter, superiority 1:1 5 yrs BMS/PES
446 (219/227)
PES superior to BMS
TYPHOON TVF at 1 yr Multicenter, superiority 1:1 4 yrs BMS/SES
712 (355/357)
SES superior to BMS
*References for each individual trial are reported in Online Table 1.
BES ¼ biolimus-eluting stent(s); BMS ¼ bare-metal stent(s); BP-BES ¼ biodegradable polymer biolimus-eluting stent(s); CoCr-EES ¼ cobalt-chromium everolimus-eluting stent(s); COMPARE ¼ A Ran-
domized Controlled Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice; C-SES ¼ Cypher sirolimus-eluting stent(s); C-SIRIUS ¼ Study of the Bx
VELOCITY Stent in the Treatment of De Novo Coronary Artery Lesions; DES ¼ drug-eluting stent(s); E-SIRIUS ¼ Study of the Bx VELOCITY Stent in Patients With De Novo Coronary Artery Lesions; E-ZES ¼
Endeavor zotarolimus-eluting stent(s); HORIZONS-AMI ¼ Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction; ISAR DESIRE ¼ Intracoronary Stenting and Angiographic
Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis; ISAR DIABETES ¼ The Intracoronary Stenting and Angiographic Results: Do Diabetic Patients Derive Similar Beneﬁt from Paclitaxel-
Eluting and Sirolimus-Eluting Stents; ISAR SMART III ¼ Intracoronary Drug-Eluting Stenting to Abrogate Restenosis in Small Arteries; ISAR TEST IV ¼ Intracoronary Stenting and Angiographic Results: Test
Efﬁcacy of 3 Limus-Eluting Stents; IVUS ¼ intravascular ultrasound; LEADERS ¼ Limus Eluted From a Durable Versus Erodable Stent Coating; MI ¼ myocardial infarction; MULTISTRATEGY ¼ Multicentre
Evaluation of Single High-Dose Bolus Tiroﬁban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study; PASEO ¼ Paclitaxel or Sirolimus-Eluting Stent Versus Bare
Metal Stent in Primary Angioplasty; PASSION ¼ Paclitaxel-Eluting Stent Versus Conventional Stent in Myocardial Infarction With ST-Segment Elevation; PC-ZES ¼ phosphorylcholine-based zotarolimus-
eluting stent(s); PES ¼ paclitaxel-eluting stent(s); PLATINUM ¼ Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of
up to Two De Novo Coronary Artery Lesions; PRISON II ¼ Primary Stenting of Totally Occluded Native Coronary Arteries II; PROSIT ¼ Prospective Randomized cOmparison of SIrolimus- versus pacliTaxel-
eluting stents for the treatment of acute STEMI; PROTECT ¼ Patient-Related Outcomes With Endeavor Versus Cypher Stenting Trial; PtCr-EES ¼ platinum chromium everolimus-eluting stent(s); RACES MI ¼
Randomized Comparison of Everolimus Eluting Stents and Sirolimus Eluting Stent in Patients With ST Elevation Myocardial Infarction; RAVEL ¼ Randomized Study With the Sirolimus-Coated Bx VELOCITY
Balloon-Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions; RESOLUTE ¼ Resolute All-Comers Trial; Re-ZES ¼ Resolute zotarolimus-eluting stent(s);
SCANDSTENT ¼ Randomized Multicenter Comparison of Sirolimus Versus Bare Metal Stent Implantation in Complex Coronary Lesions; SCORPIUS ¼ German Multicenter, Randomized, Controlled, Open-Label
Study of the Cypher Sirolimus-Eluting Stent in the Treatment of Diabetic Patients With De Novo Native Coronary Artery Lesions; SES ¼ sirolimus-eluting stent(s); SESAMI ¼ Sirolimus-Eluting Stent in Acute
Myocardial Infarction; SIRIUS ¼ Multicenter, Randomized, Double-Blind Study of the Sirolimus-Eluting Balloon-Expandable Stent in the Treatment of Patients With De Novo Native Coronary-Artery Lesions;
SIRTAX LATE ¼ Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization extended follow-up; SORT OUT ¼ Scandinavian Organization for Randomized Trials With Clinical Outcome;
SOS¼ Stenting of Saphenous Vein Grafts; SPC-ZES¼ phosphorylcholine polymer based zotarolimus-eluting stent(s); SPIRIT¼ Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in
the Treatment of Patients With de Novo Native Coronary Artery Lesions; ST ¼ stent thrombosis; STRATEGY ¼ Single High-Dose Bolus Tiroﬁban and Sirolimus Eluting Stent Versus Abciximab and Bare Metal
Stent in Acute Myocardial Infarction; TAXI ¼ Prospective Randomized Comparison Between Paclitaxel and Sirolimus Stents in the Real World of Interventional Cardiology; TAXUS ¼ Randomized, Double-
Blind, Controlled Study of the Safety and Performance of the NIRx Paclitaxel-Coated Conformer Coronary Stent; TLF ¼ target-lesion failure, deﬁned as cardiac death, target-vessel MI, or TLR; TLR ¼ target-
lesion revascularization; TVF¼ target-vessel failure, deﬁned as cardiac death, target-vessel MI, or TVR; TVR¼ target-vessel revascularization; TYPHOON¼ Trial to Assess the Use of the Cypher Stent in Acute
Myocardial Infarction Treated With Balloon Angioplasty.
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FIGURE 2 Pooled HR and 95% CIs Determined by Network Meta-Analysis for Deﬁnite
ST, Deﬁnite/Probable ST, Very Late Deﬁnite ST, and Very Late Deﬁnite/Probable ST
B Definite or Probable ST
BES vs SES
BES vs BMS
BES vs PES
PC-ZES vs SES
PC-ZES vs SES
CoCr-EES vs PES
CoCr-EES vs SES
CoCr-EES vs BMS
0.1 101
Favors Stent 1 Favors Stent 2
Favors Stent 1 Favors Stent 2
HR (95% CI)
0.50 (0.33–0.73)
0.56 (0.32–0.95)
0.48 (0.34–0.65)
0.53 (0.31–0.89)
0.68 (0.48–1.00)
0.52 (0.35–0.72)
0.58 (0.35–0.92)
0.68 (0.48–1.00)
A Definite ST
PC-ZES vs SES
CoCr-EES vs SES
CoCr-EES vs BES
CoCr-EES vs PES
CoCr-EES vs BMS
0.1 101
HR (95% CI)
0.48 (0.29–0.82)
0.42 (0.27–0.64)
0.55 (0.36–0.93)
0.41 (0.26–0.64)
0.58 (0.31–1.00)
After a median follow-up of 3.8 years, hazard ratios (HRs) and credible intervals (CIs) were
assessed for the risk of (A) deﬁnite stent thrombosis (ST), (B) deﬁnite/probable ST, (C)
very late deﬁnite ST, and (D) very late deﬁnite/probable ST. Only statistically signiﬁcant
differences are shown. Abbreviations as in Figure 1.
Continued on the next page
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2500Therapeutics (TCT) website, the Clinical Trials
website, the Clinical Trial Results website, the
American College of Cardiology website, and ab-
stracts and presentations from major cardiovascular
meetings, such as TCT, EuroPCR, American College
of Cardiology, American Heart Association, and
TCTAP, using the keywords randomized clinical
trial, drug-eluting stent, biolimus-eluting stent, ever-
olimus-eluting stent, paclitaxel-eluting stent, siroli-
mus-eluting stent, zotarolimus-eluting stent, and
bare-metal stent. Two investigators (T.P. and D.D.R.)
independently reviewed the titles, abstracts, and
studies to determine whether they met the inclu-
sion criteria. Conﬂicts between reviewers wereresolved by consensus. No language, publication
date, or publication status restrictions were
imposed. The most updated data for a given study
were selected. Internal validity of RCTs was
assessed by evaluating concealment of allocation,
blind adjudication of ST, and inclusion of all ran-
domized patients in the analysis according to the
intention-to-treat principle.
STATISTICAL ANALYSIS. Network meta-analysis was
performed within a bayesian framework computing
hazard ratio (HR) and 95% credible intervals (CIs)
with a random-effect hierarchical model by means of
Markov chain Monte Carlo methods with Gibbs sam-
pling from 1,000 iterations obtained after a 5,000-
iteration training phase. Convergence was appraised
graphically according to Gelman and Rubin. Model
ﬁt was assessed by use of the deviance information
criterion. Inconsistency was assessed by contrasting
direct evidence with indirect evidence from the
entire network on each node (node splitting). The
measure of conﬂict p was implemented using Markov
chain Monte Carlo by counting the proportion of
times the direct treatment effect exceeded the
indirect treatment effect. Analysis of heterogeneity
for the given network was performed with per-
comparison I2 statistics. Small study effects were
explored by inspecting comparison-adjusted funnel
plots. Bayesian Markov chain Monte Carlo simulations
were performed by means of JAGS software in R
using GeMTC (R package version 0.6) and rjags
(R package version 3-13). Funnel plots were obtained
in RevMan 5 (The Cochrane Nordic Center, Copenha-
gen, Denmark).
RESULTS
The ﬂow diagram of the study analysis is shown in
Online Figure 1. Of 2,815 potentially relevant articles
initially screened, 51 trials met the inclusion criteria
and were included in the ﬁnal meta-analysis, with a
total of 52,158 randomized patients. The evidence
network is shown in Figure 1. The major characteris-
tics of the included trials appear in Table 1. Median
follow-up (determined as described previously) was
3.8 years (range 3 to 6 years) (27). The major inclusion
and exclusion criteria and internal validity assess-
ment for each trial are reported in Online Table 1.
The clinical characteristics of patients enrolled in the
RCTs included in the meta-analysis are reported in
Online Table 2. Updated RCTs with extended follow-
up compared with prior reports are shown in Online
Table 3.
LONG-TERM ST. As shown in Figure 2 and Table 2, at a
median follow-up duration of 3.8 years, CoCr-EES
FIGURE 2 Continued
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2501were associated with lower rates of deﬁnite ST than
BMS (HR: 0.48; 95% CI: 0.29 to 0.82), PES (HR: 0.42;
95% CI: 0.27 to 0.64), and SES (HR: 0.41; 95% CI:
0.26 to 0.64). A borderline signiﬁcant reduction in
deﬁnite ST was apparent with CoCr-EES compared
with BES (HR: 0.58; 95% CI: 0.31 to 1.00). PC-ZES
were associated with signiﬁcantly lower rates of
deﬁnite ST than SES (HR: 0.55; 95% CI: 0.36 to 0.93).
Similar results were apparent when the broader
deﬁnition of deﬁnite/probable ST was considered. In
addition, BES were associated with lower rates of
deﬁnite/probable ST than BMS (HR: 0.56; 95% CI:
0.32 to 0.95), PES (HR: 0.53; 95% CI: 0.31 to 0.89),
and SES (HR: 0.58; 95% CI: 0.35 to 0.92). BMS,
PC-ZES, and CoCr-EES were associated with lower
rates of very late deﬁnite ST than PES and SES.
Similar results were apparent for very late deﬁnite/
probable ST. The number of deﬁnite and deﬁnite/
probable STs associated with each stent type in
pooled pairwise comparisons is reported in Online
Table 4. Visual inspection of funnel plots did
not suggest any small study effects or publication
bias (Online Figure 2).
OTHER CLINICAL OUTCOMES. At a median follow-up
of 3.8 years, CoCr-EES were associated with border-
line lower rates of death than SES, PES, or BMS and
lower rates of cardiac death than BMS. CoCr-EES also
were associated with lower rates of MI than BMS,
SES, or PES (Figure 3, Table 3). Re-ZES, PC-ZES, and
SES were associated with lower rates of MI than PES.
PC-ZES also were associated with borderline signiﬁ-
cant reductions in cardiac death and MI compared
with BMS. All DES were associated with lower rates
of TVR than BMS. In addition, CoCr-EES, PtCr-EES,
SES, and BES were associated with lower rates of
TVR than PES, and CoCr-EES were associated with a
borderline reduction in TVR compared with PC-ZES.
The number of adverse events associated with each
stent type in pooled pairwise comparisons is reported
in Online Table 5.
DISCUSSION
With a median follow-up of nearly 4 years, the pre-
sent study is the largest, most comprehensive report
to date comparing the long-term safety and efﬁcacy
between different types of DES and between DES
and BMS. The principal ﬁnding is that second-
generation DES have eliminated the late safety is-
sues that became apparent with ﬁrst-generation DES,
and even demonstrate a substantially improved late
safety and efﬁcacy proﬁle compared with BMS.
Speciﬁcally, 1) CoCr-EES were associated with lowerrates of long-term deﬁnite ST than BMS, PES, SES,
and BES, whereas PC-ZES were associated with
lower rates of deﬁnite ST than SES; 2) CoCr-EES
were associated with lower rates of long-term death
than BMS, PES, and SES and with lower rates of MI
than BMS, SES, and PES, whereas PC-ZES, SES, and
Re-ZES were associated with signiﬁcantly lower rates
of MI than PES; and 3) all DES were associated
with signiﬁcantly lower rates of TVR than BMS; in
addition, CoCr-EES, SES, PtCr-EES, and BES were
associated with lower rates of TVR than PES,
and CoCr-EES had lower rates of TVR than PC-ZES
(Central Illustration).
RCTs, observational studies, and meta-analyses
have suggested that second-generation DES have a
better safety and efﬁcacy proﬁle than ﬁrst-generation
DES (12,28,29). In addition, recent network meta-
analyses have suggested that the second-generation
permanent polymer-based CoCr-EES may be associ-
ated with lower rates of ST not only compared with
ﬁrst-generation DES but also compared with bio-
absorbable polymer-based BES and BMS (4,7,30);
however, follow-up was limited to 1 year in most of
TABLE 2 Estimates of Risk of ST According to Various Deﬁnitions Between Different DES and BMS
Deﬁnite ST Deﬁnite/Probable ST Very Late Deﬁnite ST
Very Late Deﬁnite/
Probable ST
No. of
Trials
PES vs. BMS 1.20 (0.80–1.70) 1.10 (0.79–1.40) 2.00 (1.00–4.10) 1.70 (0.95–3.00) 6
SES vs. BMS 1.20 (0.81–1.70) 0.97 (0.71–1.30) 2.90 (1.50–6.30) 2.30 (1.30–4.10) 11
Re-ZES vs. BMS 1.10 (0.37–3.70) 0.81 (0.34–1.70) 0.68 (0.09–4.60) 0.68 (0.16–2.40) 0
PC-ZES vs. BMS 0.65 (0.39–1.20) 0.66 (0.44–1.10) 0.34 (0.10–1.00) 0.49 (0.20–1.20) 1
PtCr-EES vs. BMS 0.64 (0.14–2.90) 0.58 (0.11–2.70) 2.60 (0.12–91.00) 1.90 (0.13–39.00) 0
CoCr-EES vs. BMS 0.48 (0.29–0.82) 0.50 (0.33–0.73) 0.92 (0.30–2.10) 0.82 (0.37–1.60) 1
BES vs. BMS 0.83 (0.45–1.60) 0.56 (0.32–0.95) 1.00 (0.31–2.80) 0.65 (0.23–1.60) 0
SES vs. PES 1.00 (0.68–1.50) 0.92 (0.70–1.20) 1.50 (0.78–3.00) 1.40 (0.76–2.30) 10
Re-ZES vs. PES 0.99 (0.32–3.20) 0.75 (0.33–1.50) 0.35 (0.05–2.10) 0.41 (0.10–1.30) 0
PC-ZES vs. PES 0.56 (0.34–1.01) 0.62 (0.42–1.02) 0.18 (0.05–0.47) 0.30 (0.12–0.65) 2
PtCr-EES vs. PES 0.55 (0.12–2.40) 0.55 (0.10–2.50) 1.40 (0.07–47.00) 1.20 (0.08–22.00) 0
CoCr-EES vs. PES 0.42 (0.27–0.64) 0.48 (0.34–0.65) 0.47 (0.18–0.89) 0.49 (0.25–0.89) 4
BES vs. PES 0.72 (0.39–1.40) 0.53 (0.31–0.89) 0.54 (0.18–1.30) 0.39 (0.15–0.93) 1
Re-ZES vs. SES 0.97 (0.32–3.20) 0.82 (0.36–1.60) 0.23 (0.03–1.40) 0.29 (0.07–0.99) 0
PC-ZES vs. SES 0.55 (0.36–0.93) 0.68 (0.48–1.00) 0.12 (0.04–0.27) 0.22 (0.10–0.44) 4
PtCr-EES vs. SES 0.55 (0.12–2.40) 0.59 (0.11–2.60) 0.88 (0.04–32.00) 0.85 (0.06–16.00) 0
CoCr-EES vs. SES 0.41 (0.26–0.64) 0.52 (0.35–0.72) 0.31 (0.11–0.64) 0.36 (0.18–0.65) 3
BES vs. SES 0.72 (0.42–1.20) 0.58 (0.35–0.92) 0.35 (0.13–0.78) 0.28 (0.11–0.66) 3
Re-ZES vs. PC-ZES 1.80 (0.52–6.00) 1.20 (0.48–2.80) 2.00 (0.25–16.00) 1.30 (0.29–5.20) 0
PtCr-EES vs. PC-ZES 0.97 (0.19–4.20) 0.84 (0.17–4.00) 7.70 (0.34–3.3e) 3.90 (0.25–79.00) 0
CoCr-EES vs. PC-ZES 0.75 (0.39–1.30) 0.75 (0.44–1.20) 2.60 (0.77–8.40) 1.70 (0.64–3.90) 0
BES vs. PC-ZES 1.30 (0.61–2.50) 0.85 (0.44–1.50) 3.00 (0.82–11.00) 1.30 (0.43–3.80) 0
PtCr-EES vs. Re-ZES 0.55 (0.10–3.10) 0.69 (0.17–3.60) 3.90 (0.13–2.1e) 3.00 (0.19–67.00) 0
CoCr-EES vs. Re-ZES 0.42 (0.15–1.20) 0.65 (0.33–1.30) 1.30 (0.22–10.00) 1.30 (0.40–4.00) 1
BES vs. RE-ZES 0.73 (0.22–2.50) 0.71 (0.31–1.70) 1.50 (0.21–14.00) 0.98 (0.24–4.40) 0
CoCr-EES vs. PtCr-EES 0.76 (0.19–3.30) 0.88 (0.20–4.30) 0.33 (0.01–5.70) 0.42 (0.02–5.10) 1
BES vs. PtCr-EES 1.30 (0.30–6.20) 0.99 (0.19–4.80) 0.38 (0.01–8.20) 0.31 (0.02–5.30) 0
CoCr-EES vs. BES 0.58 (0.31–1.00) 0.89 (0.55–1.50) 0.86 (0.31–2.30) 1.30 (0.51–3.30) 1
Values are hazard ratio (95% credible interval). Statistically signiﬁcant comparisons are highlighted in bold.
Abbreviations as in Table 1.
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2502these reports, with very few studies reporting data
beyond 2 years. Late events accruing after the ﬁrst
year have been reported with second-generation
DES, which calls into question the durability of the
beneﬁts of even these new devices (8,11). With the
exception of the PROTECT study, which compared
the 4-year outcomes of SES and PC-ZES (6,7), the
long-term safety and efﬁcacy of second-generation
DES have not been investigated in adequately pow-
ered studies, and therefore, whether they maintain
their absolute beneﬁt compared with ﬁrst-generation
DES and BMS remains unclear.
To address these issues, we undertook the present
large-scale, comprehensive network meta-analysis,
which included 51 RCTs with more than 50,000 ran-
domized patients with $3 year follow-up. The present
analysis has substantially increased the period of
surveillance after stent implantation from a median
of 1.7 years in previous reports (7,31) to 3.8 years in
the current study. The main ﬁnding of the present
study is that the previously noted safety and efﬁcacybeneﬁts of second-generation DES compared with
both ﬁrst-generation DES and BMS are maintained
with longer-term follow-up. In particular, after a
median follow-up of almost 4 years, CoCr-EES were
associated with lower rates of deﬁnite ST and MI
than BMS, SES, and PES. CoCr-EES were also asso-
ciated with lower rates of mortality than BMS, PES,
and SES and lower rates of TVR than BMS, PES, and
PC-ZES.
Among the other second-generation DES, PC-ZES
were associated with lower rates of deﬁnite ST
than SES, lower rates of MI than BMS and PES, and
clear efﬁcacy (TVR) compared with BMS. Although
previous studies demonstrated higher rates of late
lumen loss with PC-ZES than with other DES within
the ﬁrst year after implantation (32,33), PC-ZES were
safe and effective over long-term follow-up in the
present analysis, although with higher TVR rates
than CoCr-EES. Of note, the long-term safety and
efﬁcacy proﬁle of the more potent Re-ZES was not
signiﬁcantly different from that of PC-ZES in the
TABLE 3 Estimates of Risk of Death, Cardiac Death, Myocardial Infarction, and Target-Vessel Revascularization With Different Types of
Drug-Eluting Stents and BMS
Death Cardiac Death Myocardial Infarction Target-Vessel Revascularization
PES vs. BMS 1.00 (0.82–1.20) 0.86 (0.71–1.04) 1.00 (0.87–1.20) 0.58 (0.50–0.67)
SES vs. BMS 0.95 (0.79–1.10) 0.86 (0.70–1.05) 0.84 (0.70–1.01) 0.44 (0.38–0.51)
Re-ZES vs. BMS 0.79 (0.52–1.20) 0.83 (0.51–1.60) 0.65 (0.42–1.02) 0.45 (0.29–0.68)
PC-ZES vs. BMS 0.88 (0.70–1.10) 0.73 (0.55–1.00) 0.77 (0.60–0.96) 0.50 (0.41–0.62)
PtCr-EES vs. BMS 0.73 (0.40–1.40) 0.45 (0.19–1.10) 0.62 (0.29–1.20) 0.34 (0.19–0.57)
CoCr-EES vs. BMS 0.81 (0.64–1.00) 0.71 (0.54–0.91) 0.66 (0.52–0.85) 0.40 (0.32–0.49)
BES vs. BMS 0.95 (0.71–1.30) 0.76 (0.55–1.04) 0.81 (0.61–1.04) 0.40 (0.30–0.52)
SES vs. PES 0.95 (0.81–1.10) 1.00 (0.83–1.20) 0.82 (0.68–0.99) 0.76 (0.66–0.88)
Re-ZES vs. PES 0.79 (0.54–1.20) 0.97 (0.60–1.80) 0.63 (0.41–0.98) 0.78 (0.51–1.20)
PC-ZES vs. PES 0.88 (0.71–1.10) 0.85 (0.64–1.10) 0.74 (0.58–0.93) 0.86 (0.71–1.10)
PtCr-EES vs. PES 0.74 (0.41–1.40) 0.53 (0.22–1.30) 0.59 (0.28–1.20) 0.58 (0.34–0.98)
CoCr-EES vs. PES 0.81 (0.68–1.00) 0.83 (0.66–1.10) 0.64 (0.52–0.78) 0.69 (0.57–0.82)
BES vs. PES 0.95 (0.74–1.30) 0.89 (0.64–1.20) 0.78 (0.59–1.02) 0.69 (0.53–0.90)
Re-ZES vs. SES 0.84 (0.56–1.20) 0.96 (0.62–1.70) 0.77 (0.51–1.20) 1.00 (0.67–1.50)
PC-ZES vs. SES 0.93 (0.76–1.10) 0.85 (0.68–1.04) 0.91 (0.75–1.10) 1.10 (0.95–1.40)
PtCr-EES vs. SES 0.77 (0.42–1.40) 0.53 (0.21–1.10) 0.71 (0.34–1.40) 0.76 (0.44–1.30)
CoCr-EES vs. SES 0.86 (0.70–1.00) 0.84 (0.68–1.01) 0.78 (0.64–0.95) 0.90 (0.75–1.10)
BES vs. SES 1.00 (0.80–1.30) 0.89 (0.66–1.10) 0.95 (0.75–1.20) 0.90 (0.72–1.10)
Re-ZES vs. PC-ZES 0.90 (0.58–1.40) 1.10 (0.71–1.90) 0.86 (0.56–1.30) 0.90 (0.57–1.40)
PtCr-EES vs. PC-ZES 0.83 (0.45–1.60) 0.62 (0.24–1.40) 0.78 (0.37–1.60) 0.67 (0.38–1.20)
CoCr-EES vs. PC-ZES 0.92 (0.71–1.20) 0.99 (0.74–1.30) 0.86 (0.67–1.10) 0.80 (0.62–1.00)
BES vs. PC-ZES 1.10 (0.82–1.50) 1.10 (0.73–1.50) 1.00 (0.79–1.40) 0.80 (0.59–1.10)
PtCr-EES vs. Re-ZES 0.92 (0.47–1.90) 0.54 (0.19–1.20) 0.93 (0.41–2.10) 0.75 (0.40–1.40)
CoCr-EES vs. Re-ZES 1.00 (0.70–1.40) 0.86 (0.56–1.30) 1.00 (0.68–1.50) 0.89 (0.61–1.30)
BES vs. RE-ZES 1.20 (0.77–1.90) 0.92 (0.50–1.50) 1.20 (0.78–2.00) 0.89 (0.57–1.40)
CoCr-EES vs. PtCr-EES 1.10 (0.62–1.90) 1.60 (0.77–3.90) 1.10 (0.56–2.20) 1.20 (0.73–1.90)
BES vs. PtCr-EES 1.30 (0.68–2.40) 1.70 (0.73–4.40) 1.30 (0.66–2.70) 1.20 (0.68–1.10)
CoCr-EES vs. BES 0.85 (0.65–1.10) 0.94 (0.70–1.30) 0.82 (0.62–1.10) 1.00 (0.77–1.30)
Values are hazard ratio (95% credible interval). Statistically signiﬁcant comparisons are highlighted in bold.
Abbreviations as in Table 1.
CENTRAL ILLUSTRATION Pooled HR and 95% CI Determined by Network Meta-Analysis After Median Follow-Up
of 3.8 Years for Risk of Deﬁnite ST and All-Cause Death
Palmerini, T. et al. J Am Coll Cardiol. 2015; 65(23):2496–507.
Only statistically signiﬁcant differences are shown. BES ¼ biolimus-eluting stent(s); BMS ¼ bare-metal stent(s); CI ¼ credible interval;
CoCr-EES ¼ cobalt-chromium everolimus-eluting stent(s); HR ¼ hazard ratio; PC-ZES ¼ phosphorylcholine polymer–based zotarolimus-eluting
stent(s); PES ¼ paclitaxel-eluting stent(s); SES ¼ sirolimus-eluting stent(s).
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FIGURE 3 Pooled HR and 95% CIs Determined by Network Meta-Analysis for Death,
Cardiac Death, and Target-Vessel Revascularization
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After a median follow-up of 3.8 years, hazard ratios (HRs) and 95% credible intervals (CIs)
were determined for the risk of (A) death, (B) cardiac death, (C) myocardial infarction, and
(D) target-vessel revascularization. Only statistically signiﬁcant differences are shown.
Abbreviations as in Figure 1.
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2504present study. Thus, early angiographic measures
might be less predictive of late-term outcomes. A
large-scale RCT of Re-ZES versus PC-ZES with
extended follow-up is required to determine the
magnitude of clinical differences between these 2
stent platforms.
Bioabsorbable polymer-based DES have been
developed to mitigate the risk of very late (>1 year)
adverse events attributable to the presence of per-
manent polymers. Among these new devices, BES
have undergone the most extensive investigation
and are in widespread use (although are not yet
approved in the United States) (22–26). Although
BES were associated with signiﬁcantly lower rates of
deﬁnite/probable ST than ﬁrst-generation DES, no
safety or efﬁcacy advantages were apparent with
BES compared with other second-generation DES.
Conversely, the signal suggesting lower rates of
deﬁnite ST with CoCr-EES than with BES that was
reported at 1 year in prior studies was still apparentat 4 years (7,34). These ﬁndings challenge the notion
that polymer bioabsorption is necessary to minimize
the risk of very late ST with metallic DES and are
consistent with in vitro studies demonstrating that
ﬂuorinated polymers are thromboresistant in blood-
contact applications (35) and cause less platelet
adhesion and activation in experimental stent
perfusion studies (36). Whether other bioabsorbable
polymers that are biodegraded faster (e.g., PLGA
that is absorbed in 3 to 4 months from the
everolimus-eluting Synergy stent compared with
PLGA that is absorbed in 6 to 9 months with
BES) will permit the potential beneﬁts of these
new devices to emerge at an earlier time period
deserves further investigation; however, in the
large-scale EVOLVE (A Prospective Randomized
Multicenter Single-Blind Non-inferiority Trial to
Assess the Safety and Performance of the Evolution
Everolimus-Eluting Monorail Coronary Stent System
for the Treatment of a De Novo Atherosclerotic
Lesion) II trial, similar rates of target-lesion failure
and ST at 1 year were noted in 1,684 patients ran-
domized to the Synergy stent versus PtCr-EES (37).
A possible factor confounding the results of
our network meta-analysis is the different duration of
dual-antiplatelet therapy between DES and BMS;
however, previous reports have suggested a signiﬁ-
cant difference in ST between CoCr-EES and either
BMS or ﬁrst-generation DES as early as 30 days (4), a
period in which all patients undergoing stent im-
plantation are treated with dual-antiplatelet therapy
irrespective of stent type. In addition, no study has
ever suggested a beneﬁt in mortality with extended
dual-antiplatelet therapy (38), and therefore, it is
unlikely that the reduced mortality with CoCr-EES
compared with BMS was inﬂuenced by different
durations of dual-antiplatelet therapy.
Of note, CoCr-EES, BES, and PC-ZESwere associated
with signiﬁcantly lower rates of very late ST compared
with ﬁrst-generation DES. The mechanisms underly-
ing these ﬁndings may be related to enhanced endo-
thelialization of second-generation DES compared
with ﬁrst-generation DES, with greater strut coverage,
less inﬂammation and chronic hypersensitivity re-
actions, and less ﬁbrin deposition (39). In addition,
some studies have suggested lower rates of late stent
fractures and late malapposition (40), as well as less
endothelial dysfunction with second-generation DES
compared with ﬁrst-generation DES (41).
STUDY LIMITATIONS. As with any meta-analysis,
our report shares the limitations of the original
studies. Moreover, by exploiting potentially com-
plex evidence network and indirect comparisons as
well as direct comparisons, network meta-analysis
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: First-generation
DES are associated with a lower risk of restenosis than BMS but a
higher risk of late stent thrombosis. Second-generation DES have
been developed with novel materials and delivery systems. By a
meta-analysis of 51 comparative trials, second-generation DES
exhibited better safety and efﬁcacy than either ﬁrst-generation
DES or BMS after a median follow-up of nearly 4 years.
TRANSLATIONAL OUTLOOK: More studies are needed to
determine whether bioresorbable vascular scaffolds can lower
the risk of late events further in patients undergoing percuta-
neous coronary revascularization.
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2505assumes that patients enrolled in the component
studies could have been sampled from the same
theoretical population and that similar comparators
between different trials have a consistent risk-beneﬁt
ratio. However, no inconsistencies were apparent
between the direct and indirect estimates for the
endpoints considered across all comparisons, which
provides strong scientiﬁc support for the reliability of
the network.
Results were analyzed on aggregate data, and
therefore, we could not assess whether all baseline
characteristics were balanced between the groups.
Estimates of risk of adverse clinical outcomes be-
tween CoCr-EES and BMS were largely on the basis
of indirect comparison and therefore should be
considered hypothesis generating; however, these
results are consistent with a recently reported in-
dividual patient-level meta-analysis from the 5
RCTs in which 4,896 patients were randomized to
CoCr-EES versus BMS, which showed reduced rates
of ST and cardiac mortality with CoCr-EES
compared with BMS (42).
Finally, several of the observed reductions in event
rates were of borderline statistical signiﬁcance, and
even greater numbers of patients with longer-term
follow-up would add greater precision to the pre-
sent results.
CONCLUSIONS
In the present network meta-analysis of 51 trials
that included 52,158 randomized patients, at median
follow-up of nearly 4 years, all DES demonstrated
superior efﬁcacy in reducing TVR compared with
BMS. Second-generation DES have substantially
improved long-term safety and efﬁcacy outcomes
compared with ﬁrst-generation devices. Among
the second-generation DES, durable ﬂuoropolymer-
based CoCr-EES were associated with the lowest
rates of long-term adverse events and maximum
efﬁcacy.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Gregg W. Stone, Columbia University Medical Cen-
ter, New York-Presbyterian Hospital, The Cardio-
vascular Research Foundation, 111 East 59th Street,
11th Floor, New York, New York 10022. E-mail:
gs2184@columbia.edu.RE F E RENCE S1. Moses JW, Leon MB, Popma JJ, et al., for the
SIRIUS Investigators. Sirolimus-eluting stents versus
standard stents in patients with stenosis in a native
coronary artery. N Engl J Med 2003;349:1315–23.2. Stone GW, Ellis SG, Cannon L, et al., for the
TAXUS V Investigators. Comparison of a polymer-
based paclitaxel-eluting stent with a bare metal
stent in patients with complex coronary arterydisease: a randomized controlled trial. JAMA
2005;294:1215–23.
3. Camenzind E, Steg PG, Wijns W. Stent throm-
bosis late after implantation of ﬁrst-generation
Palmerini et al. J A C C V O L . 6 5 , N O . 2 3 , 2 0 1 5
Long-Term Safety of DES Versus BMS J U N E 1 6 , 2 0 1 5 : 2 4 9 6 – 5 0 7
2506drug-eluting stents: a cause for concern. Circula-
tion 2007;115:1440–55.
4. Palmerini T, Biondi-Zoccai G, Della Riva D,
et al. Stent thrombosis with drug-eluting
and bare-metal stents: evidence from a com-
prehensive network meta-analysis. Lancet 2012;
379:1393–402.
5. Sabate M, Cequier A, Iñiguez A, et al. Everolimus-
eluting stent versus bare-metal stent in ST-segment
elevation myocardial infarction (EXAMINATION): 1
year results of a randomised controlled trial. Lancet
2012;380:1482–90.
6. Camenzind E, Wijns W, Mauri L, et al., for the
PROTECT Steering Committee and Investigators.
Stent thrombosis and major clinical events at
3 years after zotarolimus-eluting or sirolimus-
eluting coronary stent implantation: a rando-
mised, multicentre, open-label, controlled trial.
Lancet 2012;380:1396–405.
7. Palmerini T, Biondi-Zoccai G, Della Riva D, et al.
Clinical outcomes with bioabsorbable polymer-
versus durable polymer-based drug-eluting and
bare-metal stents: evidence from a comprehensive
network meta-analysis. J Am Coll Cardiol 2014;63:
299–307.
8. Brener SJ, Kereiakes DJ, Simonton CA, et al.
Everolimus-eluting stents in patients undergoing
percutaneous coronary intervention: ﬁnal 3-year
results of the Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System in the
Treatment of Subjects With de Novo Native Cor-
onary Artery Lesions trial. Am Heart J 2013;166:
1035–42.
9. Christiansen EH, Jensen LO, Thayssen P, et al.
Biolimus-eluting biodegradable polymer-coated
stent versus a durable polymer-coated sirolimus-
eluting stent in unselected patients receiving
percutaneous coronary intervention. SORT-OUT V:
3-year outcome. Lecture presented at: EuroPCR;
May 21, 2014; Paris, France.
10. Di Lorenzo E, Sauro R, Varricchio A, et al.
Randomized comparison of everolimus-eluting
stents and sirolimus-eluting stents in patients
with ST elevation myocardial infarction: RACES-MI
trial. J Am Coll Cardiol Intv 2014;7:849–56.
11. Gada H, Kirtane AJ, Newman W, et al. 5-year
results of a randomized comparison of XIENCE V
everolimus-eluting and TAXUS paclitaxel-eluting
stents: ﬁnal results from the SPIRIT III trial (clin-
ical evaluation of the XIENCE V everolimus eluting
coronary stent system in the treatment of patients
with de novo native coronary artery lesions). J Am
Coll Cardiol Intv 2013;6:1263–6.
12. Jensen LO, Thayssen P, Christiansen EH, et al.
Improved Safety and Reduction in Stent Throm-
bosis after Everolimus-Eluting Stents versus
Sirolimus-Eluting Stents in Patients with Coronary
Artery Disease: SORT OUT IV 5-Year (abstr). J Am
Coll Cardiol 2014;64 Suppl:B186–7.
13. Kirtane AJ, Leon MB, Ball MW, et al., for the
ENDEAVOR IV Investigators. The “ﬁnal” 5-year
follow-up from the ENDEAVOR IV trial comparing
a zotarolimus-eluting stent with a paclitaxel-
eluting stent. J Am Coll Cardiol Intv 2013;6:
325–33.
14. Maeng M, Tilsted HH, Jensen LO, et al. Differ-
ential clinical outcomes after 1 year versus 5 yearsin a randomised comparison of zotarolimus-eluting
and sirolimus-eluting coronary stents (the
SORT OUT III study): a multicentre, open-label,
randomised superiority trial. Lancet 2014;383:
2047–56.
15. Onuma Y, Miquel-Hebert K, Serruys PW, for
the SPIRIT II Investigators. Five-year long-term
clinical follow-up of the XIENCE V everolimus-
eluting coronary stent system in the treatment
of patients with de novo coronary artery disease:
the SPIRIT II trial. EuroIntervention 2013;8:
1047–51.
16. Smits P, Sheikjoesoef K, Royaards K, et al. Final
ﬁve year results from the all-comer COMPARE
trial: a prospective, randomized trial of ever-
olimus-eluting vs. paclitaxel-eluting stents
(abstr). J Am Coll Cardiol 2013;62 Suppl 1:B5,
http://dx.doi.org/10.1016/j.jacc.2013.08.741.
17. Vlachojannis GJ, Smits PC, Hofma SH, et al.
Abluminal biodegradable polymer biolimus-eluting
stent versus durable polymer everolimus-eluting
stent: 3 year follow-up from the COMPARE II trial
(abstr). J Am Coll Cardiol 2014;64 Suppl:B5.
18. Taniwaki M, Stefanini GG, Silber S, et al., on
behalf of the RESOLUTE All-Comers Investigators.
4-year clinical outcomes and predictors of repeat
revascularization in patients treated with new-
generation drug-eluting stents: a report from the
RESOLUTE All-Comers trial (A Randomized Com-
parison of a Zotarolimus-Eluting Stent With an
Everolimus-Eluting Stent for Percutaneous Coro-
nary Intervention). J Am Coll Cardiol 2014;63:
1617–25.
19. Tebaldi M, Arcozzi C, Campo G, Percoco G,
Ferrari R, Valgimigli M, for the STRATEGY In-
vestigators. The 5-year clinical outcomes after
a randomized comparison of sirolimus-eluting
versus bare-metal stent implantation in patients
with ST-segment elevation myocardial infarction.
J Am Coll Cardiol 2009;54:1900–1.
20. Wijns W, Steg PG, Mauri L, et al. Endeavour
zotarolimus-eluting stent reduces stent throm-
bosis and improves clinical outcomes compared
with cypher sirolimus-eluting stent: 4-year results
of the PROTECT randomized trial. Eur Heart J
2014;35:2812–20.
21. Cutlip DE, Windecker S, Mehran R, et al., on
behalf of the Academic Research Consortium.
Clinical end points in coronary stent trials: a case
for standardized deﬁnitions. Circulation 2007;115:
2344–51.
22. Chevalier B, Serruys PW, Silber S, et al. Rand-
omised comparison of Nobori, biolimus A9-eluting
coronary stent with a Taxus, paclitaxel-eluting
coronary stent in patients with stenosis in
native coronary arteries: the Nobori 1 trial. Euro-
Intervention 2007;2:426–34.
23. Chevalier B, Silber S, Park SJ, et al., for the
NOBORI 1 Clinical Investigators. Randomized
comparison of the Nobori Biolimus A9-eluting
coronary stent with the Taxus Liberté paclitaxel-
eluting coronary stent in patients with stenosis
in native coronary arteries: the NOBORI 1 trial–
Phase 2. Circ Cardiovasc Interv 2009;2:188–95.
24. Christiansen EH, Jensen LO, Thayssen P,
et al., for the Scandinavian Organization for
Randomized Trials with Clinical Outcome
(SORT OUT) V Investigators. Biolimus-elutingbiodegradable polymer-coated stent versus du-
rable polymer-coated sirolimus-eluting stent in
unselected patients receiving percutaneous
coronary intervention (SORT OUT V): a rando-
mised non-inferiority trial [published correction
appears in Lancet 2013;382:310]. Lancet 2013;
381:661–9.
25. Smits PC, Hofma S, Togni M, et al. Abluminal
biodegradable polymer biolimus-eluting stent
versus durable polymer everolimus-eluting stent
(COMPARE II): a randomised, controlled, non-
inferiority trial. Lancet 2013;381:651–60.
26. Windecker S, Serruys PW, Wandel S, et al.
Biolimus-eluting stent with biodegradable poly-
mer versus sirolimus-eluting stent with durable
polymer for coronary revascularisation (LEADERS):
a randomised non-inferiority trial. Lancet 2008;
372:1163–73.
27. GillenS, SchusterT,MeyerZumBuschenfeldeC,
Friess H, Kleeff J. Preoperative/neoadjuvant ther-
apy in pancreatic cancer: a systematic review and
meta-analysis of response and resection percent-
ages. PLoS Med 2010;7:e1000267.
28. Palmerini T, Kirtane AJ, Serruys PW, et al.,
for the SPIRIT IV Investigators. Stent thrombosis
with everolimus-eluting stents: meta-analysis of
comparative randomized controlled trials. Circ
Cardiovasc Interv 2012;5:357–64.
29. Stone GW, Rizvi A, Newman W, et al., for the
SPIRIT IV Investigators. Everolimus-eluting versus
paclitaxel-eluting stents in coronary artery dis-
ease. N Engl J Med 2010;362:1663–74.
30. Bangalore S, Kumar S, Fusaro M, et al. Short-
and long-term outcomes with drug-eluting and
bare-metal coronary stents: a mixed-treatment
comparison analysis of 117 762 patient-years of
follow-up from randomized trials. Circulation
2012;125:2873–91.
31. Kang SH, Park KW, Kang DY, et al., for the
ENDEAVOR III Investigators. Biodegradable-poly-
mer drug-eluting stents vs. bare metal stents vs.
durable-polymer drug-eluting stents: a systematic
review and Bayesian approach network meta-
analysis. Eur Heart J 2014;35:1147–58.
32. Kandzari DE, Leon MB, Popma JJ, et al., for
the ENDEAVOR III Investigators. Comparison of
zotarolimus-eluting and sirolimus-eluting stents
in patients with native coronary artery disease: a
randomized controlled trial. J Am Coll Cardiol
2006;48:2440–7.
33. Leon MB, Mauri L, Popma JJ, et al., for the
ENDEAVOR IV Investigators. A randomized com-
parison of the ENDEAVOR zotarolimus-eluting
stent versus the TAXUS paclitaxel-eluting stent
in de novo native coronary lesions 12-month out-
comes from the ENDEAVOR IV trial. J Am Coll
Cardiol 2010;55:543–54.
34. Bangalore S, Toklu B, Amoroso N, et al. Bare
metal stents, durable polymer drug eluting
stents, and biodegradable polymer drug eluting
stents for coronary artery disease: mixed treat-
ment comparison meta-analysis. BMJ 2013;347:
f6625.
35. Liu T, Lin W, Huang L, Chen S, Yang M. Surface
characteristics and hemocompatibility of PAN/
PVDF blend membranes Polym Adv Technol
2005;16:413–9.
J A C C V O L . 6 5 , N O . 2 3 , 2 0 1 5 Palmerini et al.
J U N E 1 6 , 2 0 1 5 : 2 4 9 6 – 5 0 7 Long-Term Safety of DES Versus BMS
250736. Kolandaivelu K, Swaminathan R, Gibson WJ,
et al. Stent thrombogenicity early in high-risk
interventional settings is driven by stent design
and deployment and protected by polymer-drug
coatings. Circulation 2011;123:1400–9.
37. Kereiakes DJ, Meredith IT, Windecker S, et al.
Primary outcomes of the EVOLVE II Trial: a pro-
spective randomized investigation of a novel bio-
absorbable polymer-coated, everolimus-eluting
coronary stent. Presented at: American Heart
Association Scientiﬁc Sessions; November 24,
2014; Chicago, Illinois. Available at: http://my.
americanheart.org/idc/groups/ahamah-public/@
wcm/@sop/@scon/documents/downloadable/ucm_
469620.pdf. Accessed December 10, 2014.
38. Palmerini T, Benedetto U, Bacchi-Reggiani L,
et al. Mortality in patients treated withextended duration dual antiplatelet therapy af-
ter drug-eluting stent implantation: a pairwise
and Bayesian network meta-analysis of ran-
domized trials. Lancet 2015 Mar 13 [E-pub
ahead of print].
39. Joner M, Nakazawa G, Finn AV, et al.
Endothelial cell recovery between comparator
polymer-based drug-eluting stents. J Am Coll
Cardiol 2008;52:333–42.
40. Pendyala LK, Yin X, Li J, Chen JP, Chronos N,
Hou D. The ﬁrst-generation drug-eluting stents
and coronary endothelial dysfunction. J Am Coll
Cardiol Intv 2009;2:1169–77.
41. Otsuka F, Vorpahl M, Nakano M, et al.
Pathology of second-generation everolimus-
eluting stents versus ﬁrst-generation sirolimus- andpaclitaxel-eluting stents in humans. Circulation
2014;129:211–23.
42. Valgimigli M, Sabaté M, Kaiser C, et al. Effects
of cobalt-chromium everolimus eluting stents or
bare metal stent on fatal and non-fatal cardio-
vascular events: patient level meta-analysis. BMJ
2014;349:g6427.
KEY WORDS bare-metal stent(s),
drug-eluting stent(s), meta-analysis,
stent thrombosis
APPENDIX For an expanded Results section
and supplemental tables and ﬁgures, please see
the online version of this article.
